Toxicology & Preclinical Services
Preclinical efficacy and toxicology capabilities at The Hamner Institutes for Health Sciences include efficacy testing of agents in short- and long-term bioassays and specialized mechanistic models (e.g. angiogenesis) to identify cancer preventive and therapeutic activities and their mechanisms of action, identify surrogate biomarkers of early and intermediate cancer lesions and target them for preventive or therapeutic modalities, and develop or validate new technologies to deliver drugs directly to lungs via inhalation/aspiration. Additional capabilities include health effects research of nanomaterials, genotoxicity of chemicals, and identification of mutagens, carcinogens, tumor promoters, reproductive toxins, neurotoxins, and angiogenic agents. Our research team has adapted many of these bioassays to evaluate different chemical classes of compounds using cell cultures/animals to enhance the extrapolation of data to humans.